Why the study?
Activin type II receptor ligands have been implicated in muscle wasting in aging and disease, but the role of these ligands and ActRII signaling in the heart remains unclear.
Does ActRII blockade restore or preserve cardiac function in models of heart failure?
Does ActRII blockade restore or preserve cardiac function in models of heart failure?
ActRII blockade restores or preserves cardiac function in multiple models of heart failure by preventing proteasome-dependent degradation of SERCA2a, highlighting a potential novel therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
ActRII blockade merits clinical evaluation in HF; extends preclinical data but leaves human efficacy open.
Roh et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: